Vallon Pharmaceuticals

Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

Shares of Vallon Pharmaceuticals Inc. VLON, +96.81% skyrocketed 89.0% on massive volume in morning trading Friday after the biopharmaceutical company said it is exploring strategic alternatives, including a possible sale of the company. Trading volume spiked to 82.8 million shares, compared with the full-day average of about 720,000 shares.

Vallon Pharmaceuticals stock is the biggest gainer and most active after exploring possible sale

Moving Image Technologies

Redbox Entertainment

Here's what you need to know about trading penny stocks on April 22nd The post Best Penny Stocks to Buy Now? 3 Climbing in Premarket Trading  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Now? 3 Climbing in Premarket Trading

Philadelphia, PA, April 22, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to evaluate strategic alternatives for the Company with the goal of maximizing shareholder value.

Vallon Pharmaceuticals Announces Review of Strategic Alternatives

Vallon Pharmaceuticals (VLON) down as SEAL study evaluating lead investigational product candidate, ADAIR, fails to meet its primary endpoint.

Vallon (VLON) Plummets as ADAIR Study Misses Primary Goal

Global b iopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and small biotech companies

Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors

- Company in ongoing disc ussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with COVID-19

Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19

- T opline data for p ivotal abuse study of the C ompany's lead investigational program ADAIR expected this quarter

Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update

– Liv e video webcast presentation on Tuesday, January 25 th at 9:00 AM ET

Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

- Survey r esults reinforce existing literature that immediate-release ( IR ) amphetamine s, such as Adderall ® , are the most commonly abused preparation of prescription stimulants

Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference

PHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will present at the virtual H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022.

Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

- Topline results f ro m p ivotal SEAL study expected in Q1 2022

Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR

iSpecimen

Petros Pharmaceuticals

Longeveron

Reliance Global Group

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge movie. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.

5 Short Squeeze Candidates To Watch: Petros Pharmaceuticals, iSpecimen Top The List Again

Greenland Technologies Holding Corporation

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE: GME) and AMC Entertainment Holdings (NYSE: AMC) are two high-profile examples of short-squeezes earlier this year.

5 Short Squeeze Candidates To Watch: Petros Pharma Tops List With 254% Cost To Borrow, One Of Highest Figures On Record

Amplify Energy Corp.

Crescent Point Energy

InMed Pharmaceuticals

Tivic Health Systems

Are these on your list of penny stocks right now? The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 5 To Watch Before Next Week

- Ongoing pivotal intranasal abuse study of l ead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022

Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Live moderated video webcast discussion among members of management and ADHD and a buse e xpert, Stephen V. Faraone, Ph.D., on T hurs day, November 18 th at 3 :00 P M ET

Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event

- Live video webcast presentation on Monday, November 15 th at 8:30 am ET

Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference

- Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant medication

Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting

- L ead program, ADAIR , advancing toward completion of patient enrollment and treatment in ongoing SEAL study

Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements

- Inaugural a ppointments include globally renowned leaders and experts on attention-deficit/hyperactivity disorder (ADHD) and stimulant abuse

Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board

Live video webcast with David Baker, President and CEO of Vallon , on Wednesday , August 18 th 12 : 30 PM ET

Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit

- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021

Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Patent bolsters intellectual property protection as Company's partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK

Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR

- Company remains on track to report p ivotal data from lead program , ADAIR, in second half 2021

Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm

News for Vallon Pharmaceuticals Stock (VLON)